As Aduhelm faces doubts, Biogen plans another pivotal trial for 2022

(By Damian Garde and Adam Feurerstein for STAT)

Biogen said Thursday that it expects to begin a large clinical trial next May to confirm the benefits of the Alzheimer’s disease treatment Aduhelm, pending clearance from U.S. regulators. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org